Denecimig (Mim8) for Hemophilia A, with or without inhibitors
The FDA is expected to decide on Denecimig for Hemophilia A, with or without inhibitors in Q3 2026, under a BLA from Novo Nordisk.
What is being decided
Novo Nordisk has a BLA under FDA review for Denecimig (Mim8) in Hemophilia A, with or without inhibitors. Under-the-skin injection to prevent bleeding episodes in adults and children with hemophilia A, including people with inhibitors (antibodies that stop standard factor VIII replacement from working). It mimics the job of factor VIII, the clotting protein people with hemophilia A lack, and can be given once a month, every two weeks or weekly from a single-use prefilled pen. Novo submitted the application in September 2025 and, in its August 4, 2026 half-year report, listed a US decision as expected in Q3 2026 without an exact date. In the pivotal FRONTIER 2 trial it significantly reduced bleeding rates compared with prior factor prophylaxis or on-demand treatment. Europe's CHMP recommended approval under the name Frehemgo on September 17, 2026.
Who this decision matters to
Hemophilia A is an X-linked bleeding disorder caused by deficiency or dysfunction of clotting factor VIII. Severity depends on factor levels, ranging from mild to severe hemorrhage. Modern factor replacement therapy and novel bypassing agents have transformed outcomes and quality of life.
Prevalence: 1 in 4,000 to 5,000 males worldwide; very rare in females. See our full Hemophilia A page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Hemophilia A treatment stands today
Factor VIII replacement therapy (plasma-derived or recombinant formulations including third and fourth generation products) remains the standard treatment, with dosing based on severity and bleeding event. Prophylactic therapy (regular infusions starting in childhood) prevents hemarthrosis and dramatically improves long-term joint outcomes, with early prophylaxis (before age 2-3 years) preserving normal joint function. Bypassing agents including activated prothrombin complex concentrate (aPCC) and recombinant factor VIIa (rFVIIa) manage inhibitor development (alloimmunization occurs in 20-30% of patients). Several non-factor medicines, given as injections under the skin, are now FDA approved to prevent bleeds. Emicizumab (Hemlibra), which does the job of missing factor VIII, was approved in November 2017. Marstacimab (Hympavzi) was approved in October 2024 for people 12 and older without inhibitors (antibodies that block replacement factor) and was expanded in June 2026 to people 6 and older with or without inhibitors. Concizumab (Alhemo) was approved in December 2024 for people 12 and older with inhibitors and was expanded in July 2025 to those without inhibitors. Fitusiran (Qfitlia) was approved in March 2025 for people 12 and older with or without inhibitors. The one-time gene therapy valoctocogene roxaparvovec (Roctavian) was FDA approved in June 2023 for some adults with severe hemophilia A, but on February 23, 2026 BioMarin announced it is voluntarily withdrawing Roctavian from the market after it could not find a buyer, a decision the company said was not related to safety or effectiveness. Prophylaxis initiated in childhood dramatically improves long-term joint health and quality of life. Work with hemophilia specialists at comprehensive care centers.
Meanwhile, 117 Hemophilia A trials are recruiting
Whatever the FDA decides here, research on Hemophilia A does not stop. A few currently enrolling studies, US sites first:
Other drugs Trial Friend tracks for Hemophilia A
Get notified when new hemophilia-a trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Denecimig?
Novo Nordisk has disclosed a decision window of Q3 2026 for Denecimig in Hemophilia A, with or without inhibitors, without an exact date.
What is Denecimig being reviewed for?
Novo Nordisk submitted a BLA for Denecimig in Hemophilia A, with or without inhibitors. Under-the-skin injection to prevent bleeding episodes in adults and children with hemophilia A, including people with inhibitors (antibodies that stop standard factor VIII replacement from working). It mimics the job of factor VIII, the clotting protein people with hemophilia A lack, and can be given once a month, every two weeks or weekly from a single-use prefilled pen. Novo submitted the application in September 2025 and, in its August 4, 2026 half-year report, listed a US decision as expected in Q3 2026 without an exact date. In the pivotal FRONTIER 2 trial it significantly reduced bleeding rates compared with prior factor prophylaxis or on-demand treatment. Europe's CHMP recommended approval under the name Frehemgo on September 17, 2026.
What happens after the Denecimig decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Novo Nordisk SEC filing. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.